10-Q quarterly report · filed Nov 5, 2025

Sabra Health Care REIT, Inc. (SBRA) Q3 2025 10-Q Quarterly Report

Short answer

Sabra Health Care REIT, Inc. (SBRA) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $92M (up 24.8% year over year) with net income of $23M.

Q3 2025 key financials · XBRL

Revenue
$92M
+24.8% YoY · +16.5% QoQ
Net income
$23M
−24.3% YoY · −65.6% QoQ
EPS (diluted)
$0.09
−25.0% YoY · −66.7% QoQ

Source: XBRL data from the Sabra Health Care REIT, Inc. (SBRA) Q3 2025 10-Q on SEC EDGAR. USD.

Sabra Health Care REIT, Inc. Q3 2025 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $189.0M (Rental $85.4M down 10%, Resident fees $92.0M up 25% YoY Q3 2025 vs Q3 2024
  • Operating expenses Q3 Senior Housing managed $65.9M up 22%, triple-net $3.7M down 13% YoY
  • Operating income impacted by $2.6M real estate impairment and $1.2M loss on debt extinguishment Q3 2025
  • Net income $22.5M Q3 2025 vs $29.8M Q3 2024; FFO stable $79.7M vs $80.5M YoY
  • Near-term outlook uncertain due to portfolio transitions, increased occupancy and rates supporting resident fees growth

Risk Factors

  • No new or updated risk factors disclosed in 10-Q; section states "None" under ITEM 5. OTHER INFORMATION
  • Regulatory compliance risk: ongoing adherence to Sarbanes-Oxley Act certifications by CEO and CFO filed (Sections 302 and 906)
  • Operational risk: potential impact of updated Articles of Amendment and Amended Bylaws filed through 2025 influencing corporate governance
  • Financial risk: Equity Distribution Agreement dated August 5, 2025, indicating capital raising activity and potential dilution or liquidity effects
  • No specific market, competitive, or currency-related risks newly highlighted or updated this quarter

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Sabra Health Care REIT, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.